GlobeNewswire

PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology

Share

Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the fimaVacc technology is accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is "Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers” and the abstract of the publication is available through this link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/abstract.

The open label Phase I study in more than 90 healthy volunteers was completed in 2019 and conducted to assess the safety, tolerability and immune response to fimaVacc with intradermal vaccination. The overall results provide proof-of-concept by demonstrating that fimaVacc enhances the immune responses to peptide and protein based vaccines in healthy volunteers. The results further support fimaVacc’s potential to enhance the cellular immune responses that are especially important for therapeutic effect of vaccines. Moreover, the study shows that fimaVacc can be safely employed in humans.

Per Walday, CEO of PCI Biotech, comments: We are delighted to publish the fimaVacc Phase I data in a high-impact immunology journal. The results of this study showed that employment of fimaVacc provided a substantial increase in the number of subjects exhibiting a T-cell response to an HPV peptide based vaccine. An improved CD8+ T-cell response was also seen with fimaVacc, which is a highly sought-after feature of therapeutic vaccination technologies. We now look forward to disseminating these results and move the fimaVacc technology into a disease setting.

The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fimaVacc in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). The results show a substantial increase in number of T-cell responders to HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The employment of fimaVacc increased the number of subjects exhibiting a T-cell response to the HPV peptide vaccine about 10-fold over what was achieved with the vaccine and adjuvant (Hiltonol) combination without fimaVacc. Moreover, the use of fimaVacc seemed to result in a more consistent and multifunctional CD8+ T-cell response.

The study was performed in collaboration with international experts, including staff at the Department of Medical Oncology at Leiden University Medical Centre (LUMC) under the leadership of Professor Sjoerd van der Burg. The Phase I study and the general development of the fimaVacc technology is supported by a grant from the Research Council of Norway (Forskningsrådet).

Contact information:    
Per Walday, CEO            
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech         
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Bavarian Nordic Reports Preliminary Financial Results for 202028.1.2021 13:19:50 CETPress release

Revenue and EBITDA in line with guidance for 2020. Year-end cash position better than guided for 2020 COPENHAGEN, Denmark, January 28, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today reported preliminary, unaudited financial results for 2020 in line with or better than the Company’s most recent guidance. Revenue for the full year is expected at approximately DKK 1,852 million, comprised of DKK 1,082 million from combined sale of Rabipur/RabAvert and Encepur, DKK 704 million from US Government sale, including JYNNEOS revenue and contract work, and finally DKK 66 million from the milestone payment from Janssen (Ebola vaccine approval).The operating result (EBITDA) is expected at approximately DKK 740 million, including other operating income of DKK 628 million from the sale of Priority Review Voucher.Cash position at year-end was approximately DKK 1,670 million, excluding unutilized credit facilities of DKK 244 million. DKK millionFY 2020 Guidance originalFY 2020 Guidance update

Bavarian Nordic offentliggør foreløbige resultater for 202028.1.2021 13:19:50 CETpressemeddelelse

Omsætning og EBITDA på linje med forventningerne til 2020. Likvider ved årets udgang var bedre end forventet. KØBENHAVN, Danmark, 28. januar 2021 – Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag foreløbige, ureviderede finansielle resultater for 2020 på linje med, eller bedre end selskabets senest udmeldte forventninger. Omsætningen for helåret forventes at være ca. DKK 1.852 mio., bestående af DKK 1.082 mio. fra det kombinerede salg af Rabipur/RabAvert og Encepur, DKK 704 mio. fra salg til den amerikanske regering, inklusive omsætning fra JYNNEOS og kontraktarbejde, samt DKK 66 mio. fra milepælsbetalingen fra Janssen (godkendelse af ebolavaccinen).Resultatet af primær drift før afskrivninger og nedskrivninger (EBITDA) forventes at være ca. DKK 740 mio., inklusive andre driftsindtægter på DKK 628 mio. fra salget af Priority Review Voucher.Likvider ved årets udgang udgjorde ca. DKK 1.670 mio., eksklusive uudnyttede kreditfaciliteter på DKK 244 mio. DKK mio. 2020 forventet oprindelig

German University Hospital Orders Nexstim NBS System with NexSpeech28.1.2021 10:40:00 CETPress release

Press release, Helsinki, 28 January 2021 at 11.40 am (EET) German University Hospital Orders Nexstim NBS System with NexSpeech Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a University Hospital in Germany has ordered a Nexstim NBS System with NexSpeech. The hospital is a new customer for Nexstim. The NBS System with NexSpeech will be used for neuroscientific research and diagnostics. Nexstim NBS System uses the unique SmartFocus® navigated transcranial magnetic stimulation (nTMS) technology which enables accurate and precise stimulation of the brain. SmartFocus® nTMS mapping conducted with NBS system is a non-invasive and accessible way of diagnosing the tumour’s or other lesion’s location. In addition to motor mapping, NBS System can be used also for locating language eloquent areas when used together with NexSpeech module. Mikko Karvinen, CEO of Nexstim, said: “I’m very happy to welcome this new hospital and its team to our SmartFocus® nTMS user communit

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS28.1.2021 10:10:00 CETPress release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-01-28Loan195Coupon1.00 %ISIN-codeSE0013546066Maturity2025-06-18 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln4,250Volume bought, SEK mln1,300Number of bids9Number of accepted bids5Average yield0.040 %Lowest accepted yield0.038 %Highest yield0.044 %% accepted at lowest yield 57.14 Auction date2021-01-28Loan1590Coupon1.00 %ISIN-codeSE0012676690Maturity2025-09-03 Tendered volume, SEK mln1,500 +/- 750 Volume offered, SEK mln5,926Volume bought, SEK mln1,500Number of bids12Number of accepted bids3Average yield0.066 %Lowest accepted yield0.061 %Highest yield0.068 %% accepted at lowest yield 29.87 Auction date2021-01-28Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln4,500Volume bought, SEK mln800Number of bids12Number of accepted bids1Average yield0.073 %Lowest accepted yield0.073 %Highest yield0.073 %% accepted at lowest yield 100.00 Auc

Share Buyback Transaction Details January 21 – 27, 202128.1.2021 10:00:00 CETPress release

Share Buyback Transaction Details January 21 – 27, 2021 January 28, 2021 - Wolters Kluwer today reports that it has repurchased 99,498 of its own ordinary shares in the period from January 21, 2021, up to and including January 27, 2021, for €6.9 million and at an average share price of €69.79. These repurchases are part of the share buyback program announced on October 30, 2020, under which we intend to repurchase shares for up to €50 million during the period starting January 4, 2021, up to and including February 22, 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 357,57525.069.91 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Associati

Rockridge Intersects 2.5 g/t Au over 13.0m containing 9.6 g/t Au over 2.0m and Makes New Gold Discovery 250m West of Main Zone; Assays Pending for Two Additional Holes28.1.2021 09:30:00 CETPress release

VANCOUVER, British Columbia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd.(TSX-V: ROCK)(OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge”) (the “Company”) is pleased to announce that it has completed a 2,965 metre diamond drilling program at its 100% owned Raney Gold Project located southwest of Timmins, Ontario, Canada (the “Raney Gold Project” or “Property”). A total of 11 drill holes were completed to evaluate the down plunge and strike extent of the Raney Gold Zone. Assays have been received for 9 of the 11 holes with gold mineralization intersected in all but two holes. Drill hole RN 20-13 returned 2.5 g/t Au over 13.0m from 133.0m to 146.0m including 3.41 g/t Au over 9.0m from 135.0m to 144.0m and including 9.6 g/t Au over 2.0m from 135.0m to 137.0m. Furthermore, exploratory drill hole RN 20-18 was a significant step out hole along strike 250m to the west of the main zone and returned 1.36 g/t Au over 9.0m from 141.0m to 150.0m including 2.1 g/t Au over 4.0m from 141.0m to

Vital Partners with Radboud University Medical Center to Deliver Next Generation VNA, a Data Orchestration Engine28.1.2021 09:00:00 CETPress release

MINNETONKA, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vital, a Canon Group company, has been awarded a contract by Radboud University Medical Center of Nijmegen, Netherlands. This announcement was preceded by an extensive, production-ready proof of concept, in which Vital proved to be a reliable partner as it successfully integrated its Vendor Neutral Archive (VNA) solution with Radboud's existing architecture and workflow. With Vital's VNA connecting Radboud's data silos, Radboud was able to promote efficiency at all levels of care. Radboud now has the ability to free key information from proprietary software, having data readily available at faster rates. This helps support Radboud's goal of ensuring every patient always receives the best care, now and in the future. “We needed a scalable vendor-agnostic solution that could consistently connect data within our systems.” says Laurens de Grootwe, a Lead Product Owner in Information Management at Radboud UMC. “We found that solution with